Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (Bard) for the treatment of patients with chronic kidney disease caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; and omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreich's ataxia It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of orphan neurological indications; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone972-865-2219
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$53.59 million
Profitability
Miscellaneous
Employees123
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
Reata Pharmaceuticals (NASDAQ:RETA) Frequently Asked Questions
What is Reata Pharmaceuticals' stock symbol?
Reata Pharmaceuticals trades on the NASDAQ under the ticker symbol "RETA."
How were Reata Pharmaceuticals' earnings last quarter?
Reata Pharmaceuticals Inc (NASDAQ:RETA) posted its earnings results on Thursday, August, 8th. The company reported ($1.14) EPS for the quarter, missing the Zacks' consensus estimate of ($1.12) by $0.02. The firm had revenue of $7.83 million for the quarter, compared to analyst estimates of $7.76 million. Reata Pharmaceuticals had a negative return on equity of 3,282.73% and a negative net margin of 410.38%. View Reata Pharmaceuticals' Earnings History.
When is Reata Pharmaceuticals' next earnings date?
What price target have analysts set for RETA?
8 brokers have issued 12 month target prices for Reata Pharmaceuticals' stock. Their predictions range from $130.00 to $254.00. On average, they expect Reata Pharmaceuticals' stock price to reach $199.50 in the next twelve months. This suggests a possible upside of 19.6% from the stock's current price. View Analyst Price Targets for Reata Pharmaceuticals.
What is the consensus analysts' recommendation for Reata Pharmaceuticals?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Reata Pharmaceuticals in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Reata Pharmaceuticals.
What are Wall Street analysts saying about Reata Pharmaceuticals stock?
Here are some recent quotes from research analysts about Reata Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is engaged in identifying, developing and commercializing product candidates which modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress and inflammation to address the unmet medical needs of serious or life-threatening diseases. Reata Pharmaceuticals, Inc. is based in Irving, United States. " (10/16/2019)
- 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $100 PT on RETA. Reata reported 4Q18 financial performance including collaboration revs of $7.9M, total expenses of $130.5M and cash of $338M. We project current cash to be sufficient to fund operations through 2020, including the three ongoing pivotal trials of bardoxalone in Alport syndrome and CTD-PAH, and omaveloxolone in Friedreich’s ataxia. We see 2019 as a potentially transformational year for the company, with two pivotal trial readouts in the second half and increasing visibility on a broadening set of bard’ indications going forward to further drive shares." (2/28/2019)
Has Reata Pharmaceuticals been receiving favorable news coverage?
News articles about RETA stock have trended very negative this week, according to InfoTrie Sentiment. The research group rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Reata Pharmaceuticals earned a news impact score of -3.2 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Reata Pharmaceuticals.
Who are some of Reata Pharmaceuticals' key competitors?
Some companies that are related to Reata Pharmaceuticals include Array Biopharma (ARRY), Elanco Animal Health (ELAN), Mylan (MYL), Ono Pharmaceutical (OPHLF), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), GALAPAGOS NV/S (GLPG), Teva Pharmaceutical Industries (TEVA), SAGE Therapeutics (SAGE), Bausch Health Companies (BHC), Perrigo (PRGO), Catalent (CTLT), Jazz Pharmaceuticals (JAZZ), Dr.Reddy's Laboratories (RDY) and Sarepta Therapeutics (SRPT).
What other stocks do shareholders of Reata Pharmaceuticals own?
Who are Reata Pharmaceuticals' key executives?
Reata Pharmaceuticals' management team includes the folowing people:
- Mr. J. Warren Huff, Chairman, CEO & Pres (Age 65)
- Dr. Colin J. Meyer, Chief Medical Officer & Exec. VP of Product Devel. (Age 40)
- Dr. Keith W. Ward, Consultant (Age 49)
- Mr. Jason D. Wilson, CFO & Exec. VP of Strategy (Age 49)
- Ms. Elaine Castellanos, VP of Fin. & Accounting
When did Reata Pharmaceuticals IPO?
(RETA) raised $60 million in an initial public offering (IPO) on Thursday, May 26th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO.
Who are Reata Pharmaceuticals' major shareholders?
Reata Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Osborn Williams & Donohoe LLC (0.27%). Company insiders that own Reata Pharmaceuticals stock include Cpmg Inc, Elaine Castellanos, James Edward Bass, James W Traweek Jr, James Warren Huff, Jason Douglas Wilson, Keith Wayne Ward and R Kent Mcgaughy Jr. View Institutional Ownership Trends for Reata Pharmaceuticals.
Which major investors are buying Reata Pharmaceuticals stock?
RETA stock was purchased by a variety of institutional investors in the last quarter, including Osborn Williams & Donohoe LLC. Company insiders that have bought Reata Pharmaceuticals stock in the last two years include Cpmg Inc, James Edward Bass, James W Traweek Jr and R Kent Mcgaughy Jr. View Insider Buying and Selling for Reata Pharmaceuticals.
How do I buy shares of Reata Pharmaceuticals?
Shares of RETA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Reata Pharmaceuticals' stock price today?
One share of RETA stock can currently be purchased for approximately $166.76.
How big of a company is Reata Pharmaceuticals?
Reata Pharmaceuticals has a market capitalization of $5.02 billion and generates $53.59 million in revenue each year. The company earns $-80,550,000.00 in net income (profit) each year or ($2.87) on an earnings per share basis. Reata Pharmaceuticals employs 123 workers across the globe.View Additional Information About Reata Pharmaceuticals.
What is Reata Pharmaceuticals' official website?
How can I contact Reata Pharmaceuticals?
Reata Pharmaceuticals' mailing address is 2801 GATEWAY DRIVE SUITE 150, IRVING TX, 75063. The company can be reached via phone at 972-865-2219 or via email at [email protected]
MarketBeat Community Rating for Reata Pharmaceuticals (NASDAQ RETA)
MarketBeat's community ratings are surveys of what our community members think about Reata Pharmaceuticals and other stocks. Vote "Outperform" if you believe RETA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RETA will underperform the S&P 500 over the long term. You may vote once every thirty days.
